The initial results in muscle-invading bladder cancer of RTOG 95-06: Phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response

Oncologist

Volumn 5, Issue 6, 2000, Pages 471-476

  Kaufman, D S ^a   Winter, K A ^a   Shipley, W U ^a   Heney, N M ^a   Chetner, M P ^a   Souhami, L ^a   Zlotecki, R A ^a   Sause, W T ^a   True, L D ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Bladder cancer; Bladder preservation; Chemotherapy; Combined modality therapy; Invasive; Radiation therapy

Indexed keywords

CISPLATIN; FLUOROURACIL;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLOOD TOXICITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CYSTECTOMY; FEMALE; HUMAN; MALE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION DOSE; TRANSURETHRAL RESECTION; TREATMENT OUTCOME;

EID: 0033663646     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.5-6-471     Document Type: Article

References (13)

1. Selective preservation by combination treatment of invasive bladder cancer
2. Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-12
3. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder. A prospective study
4. An organ-sparing treatment of advanced bladder cancer. A 10-year experience
5. Neoadjuvant combined modality therapy with possible organ preservation for invasive bladder cancer
6. Bladder preservation by combined modality therapy for invasive bladder cancer
7. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03
8. A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil, and twice-a-day radiation followed by selective bladder preservation in operable patients with muscle-invading bladder cancer
9. Nonparametric estimation from incomplete observations
10. A class of K-sample tests comparing the cumulative incidence of a competing risk
11. Concomitant 5-fluorouracil, cisplatin and bifractionated split course radiation therapy for invasive bladder cancer
12. An update of combined modality therapy for patients with muscle invading bladder cancer using either selective bladder preservation or cystectomy
13. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer